Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study.
SARS-CoV-2
COVID-19
mortality
viral load
viremia
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
received:
16
07
2020
accepted:
26
08
2020
pubmed:
29
8
2020
medline:
9
11
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). This study aimed to determine if SARS-CoV-2 RNA in serum at admission correlated with clinical outcome in COVID-19. COVID-19 patients admitted to the infectious diseases department of a tertiary level Swedish hospital and sampled for SARS-CoV-2 RNA in serum at admission during 10 April to 30 June 2020 were included. Primary outcomes were day 28 all-cause mortality and progress to critical disease. The cohort (N = 167) consisted of 106 SARS-CoV-2 RNA serum-negative and 61 serum-positive patients. Median sampling time for initial SARS-CoV-2 in serum was 1 day (interquartile range [IQR], 1-2 days) after admission, corresponding to day 10 (IQR, 8-12) after symptom onset. Median age was 53 years (IQR, 44-67 years) and 63 years (IQR, 52-74 years) for the serum-negative and -positive patients, respectively. In the serum-negative and -positive groups, 3 of 106 and 15 of 61 patients died, respectively.The hazard ratios for critical disease and all-cause mortality were 7.2 (95% confidence interval [CI], 3.0-17) and 8.6 (95% CI, 2.4-30), respectively, for patients with serum-positive compared to serum-negative results. SARS-CoV-2 RNA in serum at hospital admission indicates a high risk of progression to critical disease and death.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). This study aimed to determine if SARS-CoV-2 RNA in serum at admission correlated with clinical outcome in COVID-19.
METHODS
COVID-19 patients admitted to the infectious diseases department of a tertiary level Swedish hospital and sampled for SARS-CoV-2 RNA in serum at admission during 10 April to 30 June 2020 were included. Primary outcomes were day 28 all-cause mortality and progress to critical disease.
RESULTS
The cohort (N = 167) consisted of 106 SARS-CoV-2 RNA serum-negative and 61 serum-positive patients. Median sampling time for initial SARS-CoV-2 in serum was 1 day (interquartile range [IQR], 1-2 days) after admission, corresponding to day 10 (IQR, 8-12) after symptom onset. Median age was 53 years (IQR, 44-67 years) and 63 years (IQR, 52-74 years) for the serum-negative and -positive patients, respectively. In the serum-negative and -positive groups, 3 of 106 and 15 of 61 patients died, respectively.The hazard ratios for critical disease and all-cause mortality were 7.2 (95% confidence interval [CI], 3.0-17) and 8.6 (95% CI, 2.4-30), respectively, for patients with serum-positive compared to serum-negative results.
CONCLUSIONS
SARS-CoV-2 RNA in serum at hospital admission indicates a high risk of progression to critical disease and death.
Identifiants
pubmed: 32856036
pii: 5898271
doi: 10.1093/cid/ciaa1285
pmc: PMC7499508
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2995-e3001Subventions
Organisme : Stockholm County Council
ID : SLL20160597
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Clin Infect Dis. 2020 Jul 28;71(15):833-840
pubmed: 32296824
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Clin Infect Dis. 2021 Nov 2;73(9):e2890-e2897
pubmed: 32803231
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Respir Med. 2020 Sep;8(9):e70
pubmed: 32771081
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EMBO Mol Med. 2020 Jul 7;12(7):e12421
pubmed: 32428990
N Engl J Med. 2016 Sep 29;375(13):1303-5
pubmed: 27682053
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Nat Med. 2004 Dec;10(12 Suppl):S88-97
pubmed: 15577937